Acemetacin compared to other nonsteroidal anti-inflammatory drugs: A literature review Review article
Article Sidebar
Published:
Oct 20, 2026
Keywords:
acemetacin, nonsteroidal anti-inflamatory drugs, pain
Main Article Content
Abstract
Acemetacin is an indoleacetic acid derivative and a prodrug of indomethacin, one of the classic, potent nonsteroidal anti-inflammatory drugs (NSAIDs). It was introduced into clinical practice to reduce adverse effects, particularly gastrointestinal toxicity, while maintaining therapeutic efficacy. The aim of this review is to compare acemetacin with other NSAIDs in terms of its mechanism of action, pharmacokinetic properties, clinical efficacy, and safety profile.
Article Details
How to Cite
Pojmańska, A. (2026). Acemetacin compared to other nonsteroidal anti-inflammatory drugs: A literature review. Medycyna Faktow (J EBM), 19(2(71), 175-182. https://doi.org/10.24292/01.MF.0226.5
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Woroń J. Acemetacyna – skuteczny lek o dobrym profilu bezpieczeństwa w farmakoterapii bólu. Med Fakt. 2024; 17(3): 393-97.
2. Panchal NK, Sabina EP. Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities. Food Chem Toxicol. 2023; 172: 113598. http://doi.org/10.1016/j.fct.2022.113598.
3. Bacchi S, Palumbo P, Sponta A et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti-inflamm Antiallergy Agents Med Chem. 2012; 11(1): 52-64. http://doi.org/10.2174/187152312803476255.
4. Chávez-Piña AE, McKnight W, Dicay M et al. Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol. 2007; 152: 930-8.
5. Todd PA, Clissold SP. Acemetacin. A reappraisal of its pharmacology and therapeutic use. Drugs. 1990; 40(1): 91-114.
6. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020; 180: 114147. http://doi.org/10.1016/j.bcp.2020.114147.
7. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. 2023.
8. Rantudil Forte 90 mg, kapsułki o przedłużonym uwalnianiu. Charakterystyka Produktu Leczniczego. Meda Pharma GmbH & Co. KG; aktualna wersja dostępna w Urzędzie Rejestracji Produktów Leczniczych (URPL).
9. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013; 19(12): 1861-76. http://doi.org/10.3748/wjg.v19.i12.1861.
10. Martínez-Lemos RI, et al. Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews. Drugs Context. 2023; 12. http://doi.org/10.7573/dic.2022-11-2.
11. Chávez-Piña AE, McKnight W et al. Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol. 2008; 155: 1051-8. http://doi.org/10.1038/bjp.2008.333.
12. Hernández-Díaz S, Rodríguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies. Arch Intern Med. 2000; 160: 2093-9.
13. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis. Drug Saf. 2012; 35: 1127-46.
14. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-79. http://doi.org/10.1016/S0140-6736(13)60900-9.
15. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8: e1001098.
16. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6): 669-81. http://doi.org/10.1517/14740330903311023.
17. Wełnicki M. Bezpieczeństwo i skuteczność stosowania niesteroidowych leków przeciwzapalnych – acemetacyna okiem internisty. Med Fakt. 2017; 10(2): 124-8.
18. Białecka M. Bezpieczeństwo i skuteczność stosowania niesteroidowych leków przeciwzapalnych – acemetacyna okiem neurologa. Med Fakt. 2017; 10(2).
19. Postuła M, Berkowicz T. Acemetacyna – skuteczność i bezpieczeństwo w praktyce klinicznej. Med Fakt. 2017; 10(3): 262-6.
20. Kocot-Kępska M, Kierzkiewicz M, Białoszewski D. Czy warto stosować acemetacynę? Spojrzenie wielodyscyplinarne. Med Fakt. 2018; 11(1): 59-62.
2. Panchal NK, Sabina EP. Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities. Food Chem Toxicol. 2023; 172: 113598. http://doi.org/10.1016/j.fct.2022.113598.
3. Bacchi S, Palumbo P, Sponta A et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti-inflamm Antiallergy Agents Med Chem. 2012; 11(1): 52-64. http://doi.org/10.2174/187152312803476255.
4. Chávez-Piña AE, McKnight W, Dicay M et al. Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol. 2007; 152: 930-8.
5. Todd PA, Clissold SP. Acemetacin. A reappraisal of its pharmacology and therapeutic use. Drugs. 1990; 40(1): 91-114.
6. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020; 180: 114147. http://doi.org/10.1016/j.bcp.2020.114147.
7. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. 2023.
8. Rantudil Forte 90 mg, kapsułki o przedłużonym uwalnianiu. Charakterystyka Produktu Leczniczego. Meda Pharma GmbH & Co. KG; aktualna wersja dostępna w Urzędzie Rejestracji Produktów Leczniczych (URPL).
9. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013; 19(12): 1861-76. http://doi.org/10.3748/wjg.v19.i12.1861.
10. Martínez-Lemos RI, et al. Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews. Drugs Context. 2023; 12. http://doi.org/10.7573/dic.2022-11-2.
11. Chávez-Piña AE, McKnight W et al. Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol. 2008; 155: 1051-8. http://doi.org/10.1038/bjp.2008.333.
12. Hernández-Díaz S, Rodríguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies. Arch Intern Med. 2000; 160: 2093-9.
13. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis. Drug Saf. 2012; 35: 1127-46.
14. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-79. http://doi.org/10.1016/S0140-6736(13)60900-9.
15. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8: e1001098.
16. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6): 669-81. http://doi.org/10.1517/14740330903311023.
17. Wełnicki M. Bezpieczeństwo i skuteczność stosowania niesteroidowych leków przeciwzapalnych – acemetacyna okiem internisty. Med Fakt. 2017; 10(2): 124-8.
18. Białecka M. Bezpieczeństwo i skuteczność stosowania niesteroidowych leków przeciwzapalnych – acemetacyna okiem neurologa. Med Fakt. 2017; 10(2).
19. Postuła M, Berkowicz T. Acemetacyna – skuteczność i bezpieczeństwo w praktyce klinicznej. Med Fakt. 2017; 10(3): 262-6.
20. Kocot-Kępska M, Kierzkiewicz M, Białoszewski D. Czy warto stosować acemetacynę? Spojrzenie wielodyscyplinarne. Med Fakt. 2018; 11(1): 59-62.